July-August 2000 Medicare B Update
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
KIDNEY FAILURE TREATMENT OPTIONS Choosing What’S Best for You What Kidneys Do
KIDNEY FAILURE TREATMENT OPTIONS Choosing What’s Best For You What Kidneys Do The kidneys are a pair of bean shaped organs located below your ribcage near the middle of your back. Kidneys play a vital role in the body by filtering blood, removing waste and extra water, balancing electrolytes—sodium, potassium, chloride, and biacarbonate, and regulating blood pressure. As kidneys filter blood they create urine/wastes which collect in the bladder until you go to the bath- room. If your body doesn’t remove these wastes, they build up in the blood and damage the body. For most people this damage occurs slowly over many years causing Chronic Kidney Disease (CKD). CKD eventually results in End Stage Renal Disease (ESRD) which is when dialysis or a transplant becomes necessary. 2 TREATMENT OPTIONS Treatment Options This guide will cover four treatment options for your condition: l Hemodialysis (in-center & home) l Peritoneal Dialysis l Kidney Transplantation l Comfort Care Introduction When diagnosed with kidney disease, the key to feeling better is to follow the treatment plan developed by your doctor and other members of your care team including nurses, dietitians, and social workers. Following the advice of your medical professionals will help you lead the healthiest lifestyle possible. When your kidneys are unable to remove extra fluid and waste from the body, dialysis is generally recommended. Dialysis helps alleviate many of the health problems people with kidney failure experience. Dialysis can be done in a hospital, a dialysis clinic, or at home. Once you know all of your treatment options, you will make the decision of where you choose to have dialysis with the help of your doctor, other health care professionals, and your family. -
Peripheral Venous Malformations with a Dominant Outflow Vein: Results of Ethanol Embolization
CASE REPORT Peripheral Venous Malformations with a Dominant Outflow Vein: Results of Ethanol Embolization Hadi Rokni-Yazdi1, Mahsa Ghajarzadeh2, Amir Hossein Keyvan3, Mohammad Javad Namavar3, and Sepehr Azizi3 1 Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imaging Medical Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran 2 Brain and Spinal Injury Repair Research Center, Tehran University of Medical Sciences, Tehran, Iran 3 Department of Infectious Diseases, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran Received: 11 Nov. 2013; Accepted: 29 Mar. 2014 Abstract- Venous malformations are the most common form of symptomatic vascular malformations. VM s could classify into low-flow lesions (VMs) and high-flow lesions (AVMs). For low-flow venous lesions, direct percutaneous puncture with injection of sclerosing agents (sclerotherapy) has been described as a successful therapy. In this article, we want to introduce a patient who treated with ethanol sclerotherapy for VM located in the right flank. The patients were a 35-year-old man with right flank mass, skin discoloration and hemorrhagic foci. Color Doppler ultrasonography showed low flow vascular malformation while Magnetic Resonance Imaging (MRI) showed that the mass contained fat tissue with branching tubular signal void structures inside. The draining vein was first coiled via tortuous venous malformation vessels access and then VM was embolized.Under ultrasonographic guide, direct puncture of one branches of venous malformation was performed, and contrast media were injected. The patient underwent the sclerotherapy every month for four consecutive months. The patient was followed up for a year, and clinical examination revealed 40-50% size reduction of the lesion while no bleeding was detected from the lesion during the follow-up period. -
Chronic Kidney Disease a Patient’S Guide
Chronic Kidney Disease A Patient’s Guide WHAT IS CHRONIC KIDNEY DISEASE (CKD)? chronic kidney disease, have heart disease or are over 60 years CKD is a preventable and treatable disease. Controlling old, you are at higher risk of CKD and should be screened for diabetes and reducing blood pressure will help you live longer this problem. and feel better. HOW IS CHRONIC KIDNEY DISEASE DIAGNOSED? The kidneys are responsible for removing liquid waste from CKD is diagnosed with (1) a blood test and (2) a urine test. the body. They are basically the body’s water filtration system. The blood test is called a glomerular filtration rate or GFR. If CKD is becoming much more common. Up to 20 million the GFR is above 60, kidney function is adequate and the risks Americans have CKD. If it is not treated early, it causes of major complications are minimal. Although not perfect, the death from heart disease, or the need for an artificial kidney easy way to remember this is that you are SAFE AT 60. machine, called dialysis. The patient may also need a kidney If the urine test shows protein, OR a GFR less than 60, then transplant. Although kidney disease cannot be cured, it can your doctor can give you a medicine called an ACE inhibi- be controlled. With some simple steps, you and your doctor tor or an ARB. These medicines will protect you from having can help to prevent heart attacks. Also, the need for dialysis or your kidney disease worsen. ACE inhibitors always end with transplant can be significantly delayed and perhaps eliminated. -
The Story of Organ Transplantation, 21 Hastings L.J
Hastings Law Journal Volume 21 | Issue 1 Article 4 1-1969 The tS ory of Organ Transplantation J. Englebert Dunphy Follow this and additional works at: https://repository.uchastings.edu/hastings_law_journal Part of the Law Commons Recommended Citation J. Englebert Dunphy, The Story of Organ Transplantation, 21 Hastings L.J. 67 (1969). Available at: https://repository.uchastings.edu/hastings_law_journal/vol21/iss1/4 This Article is brought to you for free and open access by the Law Journals at UC Hastings Scholarship Repository. It has been accepted for inclusion in Hastings Law Journal by an authorized editor of UC Hastings Scholarship Repository. The Story of Organ Transplantation By J. ENGLEBERT DUNmHY, M.D.* THE successful transplantation of a heart from one human being to another, by Dr. Christian Barnard of South Africa, hias occasioned an intense renewal of public interest in organ transplantation. The back- ground of transplantation, and its present status, with a note on certain ethical aspects are reviewed here with the interest of the lay reader in mind. History of Transplants Transplantation of tissues was performed over 5000 years ago. Both the Egyptians and Hindus transplanted skin to replace noses destroyed by syphilis. Between 53 B.C. and 210 A.D., both Celsus and Galen carried out successful transplantation of tissues from one part of the body to another. While reports of transplantation of tissues from one person to another were also recorded, accurate documentation of success was not established. John Hunter, the father of scientific surgery, practiced transplan- tation experimentally and clinically in the 1760's. Hunter, assisted by a dentist, transplanted teeth for distinguished ladies, usually taking them from their unfortunate maidservants. -
Sclerotherapy Treatment for Spider Veins
Columbus, IN 47201 Columbus, 220 • Suite 2325 18th St. Inc Southern Indiana Surgery, Hours Monday through Friday, 8 a.m. – 5 p.m. For more information, please discuss your symptoms with your primary care physician or call Southern Indiana Surgery at (800) 815-7671. Fair Oaks Mall Central Ave. Central 25th St. Hawcreek Ave. Hawcreek Columbus 18th St. Regional Health ★ 17th St. Southern Indiana Surgery Sclerotherapy Treatment for Spider Veins 2325 18th St. • Suite 220 • Columbus, IN 47201 (812) 372-2245 • (800) 815-7671 www.sisurgery.com/veins Spider veins are unsightly red or blue veins that usually appear on the thighs, calves and ankles. While they may How Many Treatment SIS Vein Clinic Surgeons not pose any health risks, the damage to self-esteem is Sessions? Douglas Y. Roese, M.D. well known in those who suffer from them. That depends on your individual needs. You may have some Vascular Center Medical Director But you don’t have to continue to suffer from spider veins. or all spider veins treated in one session, or it may take as Dr. Douglas Roese brings 15 years of Southern Indiana Surgery now offers sclerotherapy to many as three sessions. Sclerotherapy is only effective on medical expertise to Southern Indiana permanently remove ugly spider veins. visible spider veins. It does not prevent future spider veins Surgery, including a vascular fellowship from appearing. from Baylor College of Medicine and eight years of general, vascular and What Is Sclerotherapy? Who Gets Spider Veins? laparoendoscopic surgery. Dr. Roese It is an elective, cosmetic procedure to treat spider veins. -
What Is Kidney Failure?
A VIDEO SERIES living WELL with kidney failure WHAT IS KIDNEY FAILURE? Contents 2 Introduction 11 What is a kidney transplant? 3 What will I learn? 12 What role do diet and medi- cines play in transplantation? 5 Who is on my healthcare team? 12 How will I pay for treatment? 7 What is kidney failure? 14 Review 7 How will I learn to cope 15 True or False with kidney failure? 16 Words To Know 8 What treatments are 21 The People on My available for kidney failure? Healthcare Team 8 What is the best 22 Questions for My treatment for me? Healthcare Team 9 What is hemodialysis? 23 About the National 10 What is peritoneal dialysis? Kidney Foundation 10 What role do diet and medicines play in dialysis? What is Kidney Failure? 1 Introduction “Living Well with Kidney Failure” is a video series created by the National Kidney Foundation to help you understand kidney failure and its treatments. There are six videos. Each video has a companion booklet to provide more information and to help you review what you’ve learned. The six videos and booklets are: How Kidney What is Failure Kidney Peritoneal Kidney Hemodialysis Living Well Affects Your Transplant Dialysis Failure? Body This booklet talks about the treatments available for kidney failure. It also describes the professionals who make up the healthcare team in hospitals, dialysis centers, and transplant centers. But, more importantly, it focuses on the role you play in your own care. That role begins with learning all you can about kidney failure and its treatment. -
Spider Vein Treatments About Sclerotherapy
Spider Vein Treatments Talk to any woman with spider veins on her legs, and she’ll probably tell you that they’re the bane of her existence. And if you’re one of the women who has them, you’re not alone: Close to 55 percent of women have some type of vein problem, according to the U.S. Department of Health and Human Services' Office on Women's Health. A combination treatment of sclerotherapy and laser usually does best for those small yet unsightly clusters of blue, red, or purple veins. Sclerotherapy is a simple procedure, where veins are injected with a sclerosing solution, which causes the veins to collapse and fade from view. Our vascular laser (Nd:YAG) is ideal for vessels around the ankles or capillaries that are too small to treat with sclerotherapy. *Pricing dependent upon density and quantity of vessels, with pricing typically starting around $250 per session. About Sclerotherapy What is sclerotherapy? Sclerotherapy is a minimally invasive procedure done by your healthcare provider to treat uncomplicated spider veins and uncomplicated reticular veins. The treatment involves the injection of a solution into the affected veins. What are varicose veins? Varicose veins are large blue, dark purple veins. They protrude from the skin and many times they have a cord-like appearance and may twist or bulge. Varicose veins are found most frequently on the legs. What are spider veins? Spider veins are very small and very fine red or blue veins. They are closer to the surface of the skin than varicose veins. They can look like a thin red line, tree branches or spider webs. -
Cardiovascular Update Insert "Volumes"
CARDIOVASCULAR SErvicES Cardiovascular Disease, Cardiovascular Surgery, and Pediatric Cardiology ROCHESTE R MINNESOTA 2008 Cardiovascular Surgery Cardiovascular Diseases PROCEDURES Total Operations 2,355 Electrophysiology Laboratory PROCEDURES On Cardiopulmonary Bypass 2,191 Diagnostic Electrophysiology 111 Off Cardiopulmonary Bypass 164 Head-up Tilt 324 Cardiac Valve Surgery 1,345 ICD Implants 491 Mitral Valve Repair 350 ICD Follow-up Checks 119 Mitral Valve Replacement 180 Pacemaker Implants 685 Aortic Valve Repair 66 Biventricular Pacemakers Implants 4 Aortic Valve Replacement 647 Biventricular ICD Implants 149 Other Valve Surgery 389 Loop Recorder Implants 29 Bioprosthetic Valve 676 Lead Extractions 82 Mechanical Prosthetic Valve 324 Radiofrequency Ablations Homograft 10 Atrial Flutter 36 Coronary Artery Bypass Grafting 773 Atrial Tachycardia 37 Congenital Heart Disease 409 Accessory Pathway/AVNRT 124 Thoracic Aortic Aneurysm Repair 226 AVN 122 Maze Procedure 187 Pulmonary Vein Isolation 421 Myectomy/Myotomy (HOCM) 153 Ventricular Tachycardia 93 Pericardiectomy 75 Mediastinal Tumor Resection 36 Cardiac Catheterization Laboratory PROCEDURES Cardiac Transplantation 25 Pediatric Diagnosis and Intervention 355 Pulmonary Thromboendarterectomy 15 Percutaneous Intervention (PCI) 1,543 Carcinoid Valve Surgery 13 High-Risk (LVAD-Supported) PCI 16 Left Ventricular Assist Devices 33 Non-PCI Intervention 330 Minimally Invasive Procedures Rotablator Procedures 45 (Robotic and Thorascopic) 200 Diagnostic Catheterization 6,503 Coronary Physiology -
2018 Cpt Coding Changes
2018 CPT CODING CHANGES | 17 2018 CPT coding changes by Samuel Smith, MD, FACS; Megan McNally, MD, FACS; and Jan Nagle, MS, RPh JAN 2018 BULLETIN American College of Surgeons 2018 CPT CODING CHANGES ignificant changes in Current Procedural Termi- data, it was determined that the code did not clearly nology (CPT)* coding will be implemented in define the intended use, leading to misreporting. There- S2018. Notably, considerable changes have been fore, the code descriptor was revised to remove the made to codes for reporting endovascular repair of terminology “sinus or fistula” from the parenthetical abdominal aorta and/or iliac arteries. This article pro- instructions and to clearly define the intended use of vides reporting information about the codes that are the code term “proud flesh” as follows ( = revised relevant to general surgery and its related specialties. code for 2018): 17250, Chemical cauterization of granulation tissue (i.e., Flaps proud flesh) Code 15732, Muscle, myocutaneous, or fasciocutane- ous flap; head and neck (i.e., temporalis, masseter muscle, New exclusionary parentheticals were added to this sternocleidomastoid, levator scapulae), was deleted and code that direct reporting for this service, including replaced with new code 15733 to more clearly describe an instruction regarding exclusion of reporting 17250 a muscle, myocutaneous, or fasciocutaneous flap that for chemical cauterization for wound hemostasis and involves one of six different named vascular pedicles. excluding use in conjunction with active wound care In addition, new code 15730 was established to describe management services (97597, 97598, 97602). 18 | a midface flap that does not involve a named vascular pedicle. -
An Implantable Bioartificial Kidney for Treating Kidney Failure
DIALYSIS ACCESS An Implantable Bioartificial Kidney for Treating Kidney Failure An innovative device that aims to provide the benefits of kidney transplantation while addressing the limited number of donor organs. BY SHUVO ROY, PHD, AND WILLIAM FISSELL, MD nd-stage renal disease (ESRD) currently affects over nection, the bioartificial kidney processes blood continu- 600,000 people in the United States, with fewer than ously, which mitigates the inconveniences and morbidities 20,000 donor organs available for transplant. This is a associated with intermittent hemodialysis. growing problem as the number of patients on the The bioartificial kidney is a two-stage system that consists Etransplant wait list is hovering at 100,000, and the prevalent of (1) a hemofiltration unit to remove toxins and (2) a renal ESRD population is increasing at 4% to 5% annually.1,2 At cell bioreactor to provide other biological functions of a present, the only alternative to kidney transplant for the healthy kidney.3 For the hemofilter, silicon nanotechnology vast majority of patients with ESRD is hemodialysis, a proce- is used to produce a highly efficient and compact mem- dure fraught with morbidity and eventual mortality. After brane, which relies on the body’s blood pressure to perform vascular access is established in the form of an arteriovenous ultrafiltration without the need for pumps or power sup- fistula, arteriovenous graft, or venous catheter, a typical in- ply. For the cell bioreactor, recent advances in the field of center hemodialysis schedule is three sessions per week for regenerative medicine are applied to grow renal tubule 3 to 5 hours per session, in which blood is pumped through cells to perform metabolic functions. -
Technological Advances in Renal Replacement Therapy: Five Years and Beyond
Technological Advances in Renal Replacement Therapy: Five Years and Beyond Anjay Rastogi* and Allen R. Nissenson† *Division of Nephrology, Department of Medicine, University of California, Los Angeles, Los Angeles, California; and †Office of the Chief Medical Officer, DaVita Inc., El Segundo, California The worldwide epidemic of chronic kidney disease shows no signs of abating in the near future. Current dialysis forms of renal replacement therapy (RRT), even though successful in sustaining life and improving quality of life somewhat for patients with ESRD, have many limitations that result in still unacceptably high morbidity and mortality. Transplantation is an excellent option but is limited by the scarcity of organs. An ideal form of RRT would mimic the functions of natural kidneys and be transparent to the patient, as well as affordable to society. Recent advances in technology, although generally in early stages of development, might achieve these goals. The application of nanotechnology, microfluidics, bioreactors with kidney cells, and miniaturized sorbent systems to regenerate dialysate makes clinical reality seem closer than ever before. Finally, stem cells hold much promise, both for kidney disease and as a source of tissues and organs. In summary, nephrology is at an exciting crossroad with the application of innovative and novel technologies to RRT that hold considerable promise for the near future. Clin J Am Soc Nephrol 4: S132–S136, 2009. doi: 10.2215/CJN.02860409 he ongoing worldwide epidemic of chronic kidney dis- more user-friendly delivery systems. In PD, introduction of ease (CKD) includes ESRD. According to recent US automated cyclers has improved convenience of the technique T Renal Data System estimates, more than 900,000 pa- for some patients, increased the practical volume of dialysate, tients worldwide have ESRD and are on renal replacement and, therefore, increased solute clearance and ultrafiltration therapy (RRT) (1). -
Review Article FIBROSIS: Case Report and Review Article
SURGICAL MANAGEMENT OF ORAL SUBMUCOUS Review Article FIBROSIS: Case Report and Review Article Dr. Nitu Shah*, Dr. Naman Pandya**, Dr. Devanshi Vaghela***, Dr. Neha Vyas**** ABSTRACT Objective: To assess the outcome of different surgical treatment modalities of Oral Submucous Fibrosis. Background: Oral Submucous Fibrosis (OSF) is a persistent, progressive, pre-cancerous condition of the oral mucosa, which is mainly related with betel quid chewing habit. OSF is strongly connected with the risk of oral cancer. Since decades, many treatment modalities are suggested and studied like medicinal treatment, intralesional injection and physiotherapy or surgical treatments with varying degrees of benefit. But complete eradication of disease is challenging. The present article shows the outcome of various surgical treatment modalities in the management of this condition. Method: In this article a total of 4 patients who were clinically and histologically diagnosed as Oral Submucous Fibrosis, grouped according to classification system for the surgical management of OSF proposed by Khanna JN and Andrade NN. Out of 4 patients 1 patient undergone fibrectomy with collagen membrane placement, 1 patient undergone fibrectomy with buccal fat pad placement ,in 1 case fibrectomy was done with Laser , in advanced cases coronoidectomy was done. Conclusion : In oral submucous fibrosis Fibrectomy followed by grafting is a one of the suggested treatment for prevention of the recurrence of the condition but advanced procedure like coronoidectomy gives better results